No Data
No Data
No Data
No Data
No Data
Express News | Wanfu Biotech Jointly Undertakes National Key R&D Program Projects
BreakingsApr 26 15:10
Express News | Wang Jihua, Chairman of Wanfu Biotech: The company has moved to “qualitative growth”
BreakingsApr 25 15:26
Wanfu Biotech (300482) Commentary on important matters: Respiratory Trilateral Testing FDA certification is expected to increase performance
Matters: Company announcement, US subsidiary “WONDFO USA CO. , LTD” Novel Coronavirus, Influenza A Virus and Influenza B Triple Test Kit WellLife COVID-19/I
華創證券Apr 24 18:11
Wanfu Biotech (300482): Continued increase in profitability, diversified layout helps high-quality growth
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 2,765 million yuan (yoy -51%), realized net profit of 488 million yuan (yoy -59%), deducted from the mother
信達證券Apr 24 11:26
Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthe
Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthening the R&D network and diversifying product layout to help the company achieve “gradual, high-quality” growth. (Mainichi Keizai Shimbun)
Zhitong FinanceApr 24 09:00
Wanfu Biotech (300482): Strong growth in conventional business, the approval of the Joint Inspection Service in the US has exceeded expectations
Event: The company released its 2023 annual report and 2024 quarterly report. Achieved operating income of 2,765 billion yuan (-51.33%) and net profit to mother of 488 million yuan (-59.26%) in 2023
銀河證券Apr 24 07:16
No Data
No Data